Strategy of antisense oligonucleotides – actual state of art in advanced clinical studies on therapy of selected neoplastic diseases

Krystyna Stec-Michalska

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2000
vol. 4

Send email

Copy url:

abstract:

Strategy of antisense oligonucleotides – actual state of art in advanced clinical studies on therapy of selected neoplastic diseases

Krystyna Stec-Michalska

Współcz Onkol (2000) vol. 4, 6 (279-284)

Online publish date: 2003/07/30

View full text Get citation

Modulation of translation process and regulation of protein biosynthesis by means of antisense oligonucleotides lay the foundation for new therapeutic strategies, among others against neoplastic diseases. The aim of this account was the presentation of molecular basis of antisense strategy, targeted against Bcl-2 protein. This protein, being expressed by bcl-2 gene, regulates the cell apoptosis and influences the uncontrolled cell proliferation. Below there is presented the state of art in clinical studies of application of antisense oligonucleotide phosphorothioates in combating those neoplastic diseases where the level of Bcl-2 is recognised as the independent key-marker of cancer progression.

keywords:

Strategy of antisense oligonucleotides – actual state of art in advanced clinical studies on therapy of selected neoplastic diseases

Krystyna Stec-Michalska

antisense oligonucleotides, Bcl-2 protein, cancer, clinical antisense therapy